Xortx announces receipt of fda orphan drug designation to treat autosomal dominant kidney disease

Calgary, alberta, april 21, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the grant of orphan drug designation for oxypurinol – “orphan-drug designation request of oxypurinol is granted for treatment of autosomal dominant polycystic kidney disease”.
XRTX Ratings Summary
XRTX Quant Ranking